News

Vibrent Health Integrates Electronic Health Records into its Digital Research Platform, Empowering Participants to Share Their Data for Clinical Research

New framework based on HL7 Fast Healthcare Interoperability Resources (FHIR) gives Standards based access to EHR data to accelerate clinical research and digital trials

FAIRFAX, Va. — Vibrent Health, a health technology startup powering the future of precision health research, announced the integration of electronic health record (EHR) data into its Digital Health Solutions Platform, a platform that enables collection of health data from broad sources including biospecimens, genomics, environment, lifestyle and behavior, and wearable device data for clinical research and trials. Vibrent Health supports leading FHIR-enabled EHR vendors such as Epic and Cerner to ensure that their systems are seamlessly interoperable with the DHS Platform. 

Access to EHR data removes barriers to health research and offers researchers valuable insight,” explained Mark Begale, vice president, Vibrent Health. “Transparent, secure access to the full history of a participant’s medical record is key to gathering whole-person data which is essential to advancing precision medicine.”

Vibrent Health’s EHR integration tools were developed to support the National Institutes of Health’s 10-year, million-person All of Us Research Program, for which Vibrent Health serves as the Participant Technology Systems Center. 

When a health research participant consents to sharing their EHR for research, Vibrent Health’s EHR tools enable researchers to access a wealth of health data via the DHS Platform.  This data can include information about diagnoses, treatments, medications, lab results and other health-related information that can provide a fuller and more accurate picture of a research participant’s health than data that is collected by researchers manually.

“Our platform’s EHR integration is built using the emerging standard of HL7 Fast Healthcare Interoperability Resources (FHIR) to give researchers the ability to access clinical records of various participants and combine that data with other data sources,” said Vibrent Health CEO Praduman “PJ” Jain. “Reusing data collected from participants’ clinical visits to health care providers helps to improve patient participation and provides the real-world evidence needed to accelerate health research.”

A major step to transformative precision medicine research, using EHR data in clinical research has the potential to bring new therapies to patients sooner and at lower cost. Access to data promises to improve safety, patient-centeredness, communication, education and equity. 

“We regularly hear from researchers that they want to access this critical data, but the costs are simply too high. Easier access to EHR integration could be the key to making a scientific discovery,” said Begale.

Recent News

07/20/2026

U.S. Department of Commerce Intends to Invest $169 Million in Tech Hubs Funding to Enhance Economic Competitiveness and National Security

Today, the U.S. Department of Commerce announced that the Economic Development Administration (EDA) intends to award $169 million across six selected Tech Hubs to advance U.S. leadership in industries essential to our economic competitiveness and national security. These projects are part of EDA’s Regional Technology and Innovation Hubs (Tech Hubs) program, which serves as a key investment in this Administration’s America First agenda, investing in regions

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE